Sign in

    Graeme Kreindler

    former Principal and Senior Equity Research Analyst at Eight Capital

    Graeme Kreindler is a former Principal and Senior Equity Research Analyst at Eight Capital, where he specialized in the North American cannabis and life sciences sectors, covering major companies such as Curaleaf Holdings, Tilray, Cresco Labs, and iAnthus Capital. Over his tenure, he issued more than 60 stock ratings, with a track record showing a success rate of approximately 28% and an average return per rating of -4.1% according to TipRanks, though he notably made a highly profitable call on Curaleaf Holdings (+340.1% in a single year). Kreindler joined Eight Capital in 2016 and served in increasingly senior roles before departing in March 2022 to join NewGen as Principal. His professional credentials include advanced securities analysis and licensing, and he is known for frequent participation on company earnings calls and industry panels.

    Graeme Kreindler's questions to iANTHUS CAPITAL HOLDINGS (ITHUF) leadership

    Graeme Kreindler's questions to iANTHUS CAPITAL HOLDINGS (ITHUF) leadership • Q2 2019

    Question

    Graeme Kreindler from Eight Capital inquired about the significant gross profit difference between the East and West regions, questioning why the East was stronger despite its production ramp-up. He also asked for a timeline on Florida's cultivation expansion and its potential impact on store growth.

    Answer

    CFO Julius Kalcevich explained that the East's strong gross profit is due to mature facilities in Massachusetts and Florida, which have been operational for over a year. He attributed the West's lower margin to the necessity of buying third-party products in Arizona and some one-time inventory charges. COO Pat Tiernan added that Florida's cultivation output is expected to increase four-fold by November, which will be sufficient to supply the planned 17 dispensaries without capacity constraints.

    Ask Fintool Equity Research AI